Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder. The company’s pipeline remains investigational, and its product candidates have not been established as safe and effective or approved for commercial use by regulatory authorities.

Founded in 2011 and headquartered in New Haven, Connecticut, Trevi conducts its research and clinical development activities through collaborations with investigators and clinical sites. The company became publicly traded on the Nasdaq under the symbol TRVI in 2019. Its operations are centered on advancing Haduvio through clinical testing and seeking potential regulatory approvals for patients with serious chronic conditions.

Key Stats

• Today's Range: $13.48 to $14.53
• 50-Day Range: $11.88 to $17.96
• 52-Week Range: $9.82 to $20.22
• Volume: 1.38 million shs
• Average Volume: 2.45 million shs
• Market Capitalization: $1.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.08
• Consensus Rating: Moderate Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 582nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Trevi Therapeutics has a consensus price target of $27.08, representing about 93.7% upside from its current price of $13.98.

Amount of Analyst Coverage

Trevi Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 9.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.28% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 4.47.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 9.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for TRVI on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,648.00 in company stock.

Percentage Held by Insiders

15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/09/2026
• 2026 Stifel Healthcare Conference: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 34
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Trevi Therapeutics: $27.08
• High Price Target: $40.00
• Low Price Target: $16.00
• Potential Upside/Downside: +93.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.59%
• Return on Assets: -22.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 37.28
• Quick Ratio: 37.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.43 per share
• Price / Book: 9.78

Miscellaneous

• Outstanding Shares: 142,480,000
• Free Float: 120,549,000
• Market Cap: $1.99 billion
• Optionable: Optionable
• Beta: 1.15